China
Canyon Bridge, K2 Venture founders join Asia SPAC wave
Two more groups featuring Asian private equity executives have listed special purpose acquisition companies (SPACs) on US bourses as interest in these structures continues to rise globally.
China biotech player Antengene raises $97m Series C
Fidelity Investments has led a $97 million Series C round for Chinese hematology and oncology biotech developer Antengene.
Investors commit $500m to China EV maker Xpeng
Chinese electric vehicle (EV) manufacturer Xpeng Motors has closed an extended Series C round of around $500 million from a group that includes Hillhouse Capital and Sequoia Capital China, as well as hedge funds Aspex Management and Coatue Management.
Sequoia leads Series B for Chinese intelligent sales player
Tungee, a Chinese sales-focused software-as-a-service (SaaS) platform, has raised RMB120 million ($17 million) in a Series B round led by Sequoia Capital China. Qiming Venture Partners also took part.
China's TuSimple wins backing from US truck maker
TuSimple, a China and US-based developer of autonomous driving technology for trucks, has received equity funding from US truck manufacturer Navistar International and entered into a partnership with the company.
DCP, Qiming support China medical devices fund
Ascendum Capital Partners, a healthcare investment firm established by DCP Capital, Qiming Venture Partners and Chinese medical devices manufacturer Venus Medtech, is looking to raise $200 million for its debut fund.
Southeast Asia macro: Encouraging minefield
Southeast Asia benefits from an enviable macro outlook versus other markets, and investment in the region is set to recover relatively quickly. But is that enough?
Asia VC: Vertex's evolving early-stage network
Vertex Holdings’ Chua Kee-Lock likens his network of VC funds seeded by the Temasek-owned entity as a distributed computer system. It will draw down more power as it grows
PE-backed Junshi Biosciences shines on Star Market debut
PE-backed Junshi Biosciences has become the first Chinese biotech company to list in Hong Kong and the mainland, following a strong debut on Shanghai's Star Market.
2Q analysis: Numbers that deceive
Asia has seen remarkable revivals in private equity investment and fundraising – though not in exits – over the past three months. A handful of large-cap situations mask a weak environment
Luckin's chairman, PE backers removed from board
The chairman and largest shareholder in scandal-hit Chinese coffee shop chain Luckin Coffee has been removed at the second attempt. Representatives of several of the company’s private equity backers have also left the board.
China cancer test kit provider gets $30m Series E
New Horizon Health, a China-based manufacturer of cancer testing kits for use at home, has raised $30 million in a Series E round of funding led by Rock Springs Capital.
China's Yingke PE raises $286m
Shanghai-based Yingke Private Equity has closed its latest renminbi-denominated fund with commitments of RMB2 billion ($286 million), primarily from insurers and other financial institutions.
Large-cap vehicles support PE fundraising revival in second quarter
Asia private equity fundraising rebounded from a seven-year low in the first quarter of the year to reach $24 billion for April through June, but commitments were concentrated on a handful of managers.
Ocumension climbs on debut after $184m Hong Kong IPO
Ocumension Therapeutics, a Chinese drug developer targeting eye diseases that counts Boyu Capital and Temasek Holdings among its backers, posted a 152% gain on debut following a HK$1.5 billion ($200 million) Hong Kong IPO.
Quan leads $80m Series A for China biotech player
Healthcare-focused VC firm Quan Capital has led an $80 million Series A round for Citrine Medicine, a Chinese biotech developer set up by Eight Roads, F-Prime Capital, and Vivo Capital.
China EV maker Li Auto pursues US listing
Li Auto, a Chinese electric vehicle manufacturer that has been backed by online-to-offline (O2O) services giant Meituan Dianping, has filed for a US IPO.
Deal focus: Cortina goes natural for debut Australia deal
Cross-border PE investor Cortina Capital has backed Australian nutritional supplements producer ATP Science with an eye to China expansion. But establishing brand recognition at home is the first step
Portfolio: CBC Group and I-Mab Biopharma
CBC Group’s stewardship of I-Mab Biopharma brings an intensely hands-on platform-based approach to a booming China biotech space often characterized by relatively passive strategies
China's Newlink raises $128m Series D
Newlink Group, operator of a platform that helps drivers in China locate the best value gas stations, has raised a RMB900 million ($128 million) Series D round led by CICC Capital. Xiaomi Corporation also participated.
China’s Harbour BioMed raises $103m Series C
Chinese biotech start-up Harbour BioMed has raised $102.8 million in Series C funding. It comes four months after it closed an extended Series B round of $75 million.
China gay dating app Blued raises $85m in US IPO
BlueCity Holdings, the VC-backed holding company for Chinese gay dating platform Blued, traded strongly after raising $84.8 million through a NASDSAQ IPO.
Chinese online art tutoring platform secures $40m
Meishubao, China’s leading online art education platform, has raised $40 million in an extended Series C round led by Tencent Holdings.
Sequoia leads $100m Series C for China's Kuaidian
Kuaidian, a Chinese interactive content provider, has raised close to $100 million in Series C funding led by Sequoia Capital China. Existing investors GGV Capital and Morningside Venture Capital re-upped.